[rt-PA versus streptokinase--Has the controversy regarding the optimal thrombolytic agent been resolved by results of the GISSI II/International rt-PA vs. Streptokinase fatality Study?].
Gulba
D C
DC
Lichtlen
P R
PR
D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D010960:Plasminogen Activators / Q000008:administration & dosage* / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D012008:Recurrence; D013300:Streptokinase / Q000008:administration & dosage* / Q000009:adverse effects; D015996:Survival Rate
D013300:Streptokinase; D010960:Plasminogen Activators
rt-PA versus Streptokinase--Ist die Kontroverse um das optimale Thrombolytikum durch die Ergebnisse der GISSI II/Internationale rt-PA vs. Streptokinase-Letalitätsstudie entschieden worden?